Physician profile
Mark A Reedy
NPI 1508944596
$5,271.42
in general payments reported to CMS, 2019-2025
30 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,405 · 2020: $1,359 · 2021: $1,440 · 2022: $339 · 2023: $179 · 2024: $47.41 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $710 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $709.60 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,132.25 | 2019-2025 | Farxiga, Airsupra |
| Allergan, INC. | $344.62 | 2019-2020 | |
| Abbvie INC. | $259.93 | 2019-2023 | |
| Lilly USA, LLC | $241.74 | 2019-2022 | |
| Pfizer INC. | $234.17 | 2019-2025 | |
| Amarin Pharma, INC. | $210.38 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $209.90 | 2019-2022 | |
| Novo Nordisk INC | $150.23 | 2019-2025 | Wegovy |
| Glaxosmithkline, LLC. | $144.33 | 2019-2024 | Arexvy, Shingrix, Bexsero |
| Sanofi-Aventis U.S. LLC | $134.91 | 2019-2021 | |
| Amgen INC. | $130.97 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.40 | 2019-2025 | Jardiance |
| Vanda Pharmaceuticals INC. | $115.20 | 2025 | Fanapt |
| Edwards Lifesciences Corporation | $114.60 | 2025 | Sapien 3 Ultra Resilia |
| Biohaven Pharmaceutical Holding Company LTD. | $105.30 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $96.39 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.09 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $84.80 | 2019-2025 | Proquad, Vaxneuvance, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.55 | 2019 | |
| Exact Sciences Corporation | $51.52 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $47.42 | 2019-2021 | |
| Medtronic, INC. | $34.77 | 2024-2025 | Intellis Adaptivestim, Venaseal |
| Mylan Specialty L.P. | $32.32 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $29.02 | 2021 | |
| Boston Scientific Corporation | $27.06 | 2025 | Watchman Flx |
| Ethicon US, LLC | $25.89 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $22.71 | 2021 | |
| Axonics, INC. | $14.68 | 2024 | Axonics |
| Currax Pharmaceuticals LLC | $11.27 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Reedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.